Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merrion, Novo Nordisk Enter GIPET Tech Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Merrion, Novo Nordisk Enter GIPET Tech Pact

Merrion Pharmaceuticals and Novo Nordisk have signed a collaboration and option agreement to evaluate the ability of Merrion's GIPET technology to boost the oral bioavailability of an undisclosed compound.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merrion Pharmaceuticals and Novo Nordisk have signed a collaboration and option agreement to evaluate the ability of Merrion’s GIPET technology to boost the oral bioavailability of an undisclosed compound. Following the feasibility studies, Novo Nordisk will have the option to license Merrion’s GIPET technology.

As part of the agreement, Merrion has granted Novo Nordisk a warrant to acquire as much as $2 million of Merrion shares. The warrant is valid for 20 business days following the signing of a license agreement.

John Lynch, chief executive officer of Merrion Pharmaceuticals, said, “We are very pleased to be entering into another agreement with Novo Nordisk with our unique GIPET technology. This agreement further strengthens the links between the two companies following the license agreements for oral GLP-1 and Insulin respectively. This, along with the other recently announced agreements with Rebel and a top 10 pharma company, means that Merrion has an additional 6 compounds in its preclinical pipeline.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters